Jingfei Ma

Dr. Jingfei Ma

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Radiology
Verified
Journal Article
Closed access
ZZZijian Zhou
Zijian Zhou
JSJeremiah Sanders
Jeremiah Sanders
JJJason Johnson
Jason Johnson
MGMaria K. Gule-Monroe
Maria K. Gule-Monroe
MCMelissa M. Chen
Melissa M. Chen
JMJingfei Ma
Jingfei Ma
Deep learning single-shot detector algorithms identified brain metastases at postcontrast MRI with high sensitivity and moderate positive predictive value, potentially assisting treatment planning ... Background Brain metastases are manually identified during stereotactic radiosurgery (SRS) treatment planning, which is time consuming and potentially challenging. Purpose To develop and investigat...

20 January 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ZZZijian Zhou
Zijian Zhou
BABeatriz E. Adrada
Beatriz E. Adrada
RCRosalind P. Candelaria
Rosalind P. Candelaria
NENabil A. Elshafeey
Nabil A. Elshafeey
MBMedine Boge
Medine Boge
JMJingfei Ma
Jingfei Ma
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Neoadjuvant systemic therapy (NAST) followed by surgery are currently standard of care for TNBC with 50-60% of patients achieving pathologic complete response (pCR). We investigated ability of deep learning (DL) on dynamic contrast enhanced (DCE) MRI and diffusion weighted imaging acquired early during NAST to predict TNBC patients’ pCR status in the breast. During the development phase using the images of 130 TNBC patients, the DL model achieved areas under the receiver operating characteristic curves (AUCs) of 0.97 ± 0.04 and 0.82 ± 0.10 for the training and the validation, respectively. The model achieved an AUC of 0.86 ± 0.03 when evaluated in the independent testing group of 32 patients. In an additional prospective blinded testing group of 48 patients, the model achieved an AUC of 0.83 ± 0.02. These results demonstrated that DL based on multiparametric MRI can potentially differentiate TNBC patients with pCR or non-pCR in the breast early during NAST.

1 June 2013 in Magnetic Resonance Imaging
Verified
Journal Article
Closed access
CCColleen M. Costelloe
Colleen M. Costelloe
JMJohn E. Madewell
John E. Madewell
VKVikas Kundra
Vikas Kundra
RHRobyn K. Harrell
Robyn K. Harrell
RBRoland L. Bassett
Roland L. Bassett
JMJingfei Ma
Jingfei Ma

1 March 2023 in Radiation
Verified
Journal Article
Open access
PDF file
KFKristine Ferrone
Kristine Ferrone
CWCharles Willis
Charles Willis
FGFada Guan
Fada Guan
JMJingfei Ma
Jingfei Ma
LPLeif Peterson
Leif Peterson
SKStephen Kry
Stephen Kry
The space radiation environment outside the protection of the Earth’s magnetosphere is severe and difficult to shield against. The cumulative effective dose to astronauts on a typical Mars mission would likely introduce risk exceeding permissible limits for carcinogenesis without innovative strategies for radiation shielding. Damaging cardiovascular and central nervous system effects are also expected in these space environments. There are many potential options for advanced shielding and risk mitigation, but magnetic shielding using superconductors offers several distinct advantages including using the conditions in space to help maintain the superconductor’s critical temperature and lower mass compared to equivalent passive shielding materials. Despite these advantages, the development of magnetic shielding technology has remained primarily in conceptual stages since the introduction of the idea in 1961. Over the last several decades, magnetic shielding has experienced periods of high and low attention by the human spaceflight community, leading to computational tools with single-use or other limitations and a non-uniform distribution of publications on the topic over time. Within the context of technology development and the surrounding space policy environment, this paper reviews and summarizes the available literature on the application of active magnetic shielding for space radiation protection, identifies challenges, and highlights areas for future research.

1 July 2023 in Radiology: Imaging Cancer
Verified
Journal Article
Closed access
KHKen-Pin Hwang
Ken-Pin Hwang
NENabil A. Elshafeey
Nabil A. Elshafeey
AKAikaterini Kotrotsou
Aikaterini Kotrotsou
HCHuiqin Chen
Huiqin Chen
JSJong Bum Son
Jong Bum Son
GRGaiane M Rauch
Gaiane M Rauch
Purpose To determine if a radiomics model based on quantitative maps acquired with synthetic MRI (SyMRI) is useful for predicting neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Materials and Methods In this prospective study, 181 women diagnosed with stage I-III TNBC were scanned with a SyMRI sequence at baseline and at midtreatment (after four cycles of NAST), producing T1, T2, and proton density (PD) maps. Histopathologic analysis at surgery was used to determine pathologic complete response (pCR) or non-pCR status. From three-dimensional tumor contours drawn on the three maps, 310 histogram and textural features were extracted, resulting in 930 features per scan. Radiomic features were compared between pCR and non-pCR groups by using Wilcoxon rank sum test. To build a multivariable predictive model, logistic regression with elastic net regularization and cross-validation was performed for texture feature selection using 119 participants (median age, 52 years [range, 26-77 years]). An independent testing cohort of 62 participants (median age, 48 years [range, 23-74 years]) was used to evaluate and compare the models by area under the receiver operating characteristic curve (AUC). Results Univariable analysis identified 15 T1, 10 T2, and 12 PD radiomic features at midtreatment that predicted pCR with an AUC greater than 0.70 in both the training and testing cohorts. Multivariable radiomics models of maps acquired at midtreatment demonstrated superior performance over those acquired at baseline, achieving AUCs as high as 0.78 and 0.72 in the training and testing cohorts, respectively. Conclusion SyMRI-based radiomic features acquired at midtreatment are potentially useful for identifying early NAST responders in TNBC. Keywords: MR Imaging, Breast, Outcomes Analysis ClinicalTrials.gov registration no. NCT02276443 Supplemental material is available for this article. © RSNA, 2023 See also the commentary by Houser and Rapelyea in this issue.

6 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
BPBikash Panthi
Bikash Panthi
BABeatriz Elena Adrada
Beatriz Elena Adrada
RCRosalind P Candelaria
Rosalind P Candelaria
MGMary S. Guirguis
Mary S. Guirguis
CYClinton Yam
Clinton Yam
GRGaiane M Rauch
Gaiane M Rauch
Early assessment of neoadjuvant systemic therapy (NAST) response for triple-negative breast cancer (TNBC) is critical for patient care in order to avoid the unnecessary toxicity of an ineffective treatment. We assessed functional tumor volumes (FTVs) from dynamic contrast-enhanced (DCE) MRI after 2 cycles (C2) and 4 cycles (C4) of NAST as predictors of response in TNBC. A group of 100 patients with stage I-III TNBC who underwent DCE MRI at baseline, C2, and C4 were included in this study. Tumors were segmented on DCE images of 1 min and 2.5 min post-injection. FTVs were measured using the optimized percentage enhancement (PE) and signal enhancement ratio (SER) thresholds. The Mann–Whitney test was used to compare the performance of the FTVs at C2 and C4. Of the 100 patients, 49 (49%) had a pathologic complete response (pCR) and 51 (51%) had a non-pCR. The maximum area under the receiving operating characteristic curve (AUC) for predicting the treatment response was 0.84 (p < 0.001) for FTV at C4 followed by FTV at C2 (AUC = 0.82, p < 0.001). The FTV measured at baseline was not able to discriminate pCR from non-pCR. FTVs measured on DCE MRI at C2, as well as at C4, of NAST can potentially predict pCR and non-pCR in TNBC patients.